Manipal Health Enterprises (CIN: U85110KA2010PLC052540), India's largest pan-India multispecialty hospital network by licensed bed capacity, has filed its Draft Red Herring Prospectus (DRHP) with SEBI. The company, which operates 49 hospitals with 13,037 licensed beds across 14 states and union territories, is preparing for an Initial Public Offering scheduled to open on 29-Jul-2026. This move marks a significant step for the healthcare giant, which serves 6.30 million patients annually and is backed by marquee institutional investors including Temasek Holdings, TPG SG Magazine, and Novo Holdings.

Company Overview

Manipal Health Enterprises is the second-largest hospital chain in India by number of hospitals and the only private hospital chain with a leadership position in three major metros: Bengaluru, Kolkata, and Pune. The company's clinical strategy is anchored around six high-acuity specialties known as CONGO-R (Cardiac Sciences, Oncology, Neurosciences, Gastro Sciences, Orthopaedics, and Renal Sciences).

As of 31-Mar-2026, the company operated:

• 49 hospitals across 14 states and union territories
• 13,037 licensed beds, with ~46.78% located in metro cities
• A workforce of 11,064 doctors, 11,048 nurses, and 6,362 paramedics

The company has been a leading consolidator in the sector, acquiring 5,548 beds through M&A between 31-Mar-2021 and 31-Mar-2026. It also boasts advanced infrastructure, including 18 soft tissue robots, 23 orthopedic and spine surgical robots, and 19 LINACs.

Offer Details

The IPO is scheduled to open on 29-Jul-2026 and close on 31-Jul-2026. The allotment date is set for 03-Aug-2026, with listing expected on 05-Aug-2026. As of the latest DRHP filing, the price band, face value, lot size, and total issue size (Fresh Issue + OFS) have not been disclosed.

Objects of the Issue

The company has outlined specific uses for the net proceeds from the issue:

Financial Highlights

Manipal Health Enterprises has demonstrated strong revenue growth over the past two years. Revenue from operations grew at a CAGR of 29.41% from ₹6,171.63 Crore in FY2024 to ₹10,335.75 Crore in FY2026. However, Profit After Tax (PAT) declined by 15.27% YoY in FY2026 to ₹916.52 Crore, despite the revenue surge.

The company achieved a negative working capital cycle of 13 days in FY2026, reflecting strong operational efficiency. However, total assets nearly doubled to ₹24,864.50 Crore in FY2026, driven by acquisitions, leading to a decline in Return on Equity (ROE) to 10.42% from 18.03% in FY2025.

Risk Factors

Investors should consider the following material risks disclosed in the DRHP:

1. Geographic Concentration: Karnataka contributed 46.40% of revenue from operations in FY2026, down from 59.98% in FY2024. Disruptions in this state could materially impact performance.
2. High Indebtedness: Outstanding borrowings stood at ₹11,185.024 Crore as of 31-May-2026, with 45.25% subject to variable interest rates. This exposes the company to interest rate fluctuations.
3. Occupancy Rates: Occupancy rates have remained flat at 64.45% in FY2026 and 64.47% in FY2025, suggesting limited headroom for organic growth without capacity expansion.
4. Regulatory Approvals: As of the Red Herring Prospectus date, 39 material approvals were pending. Failure to obtain these could lead to operational restrictions.
5. Acquisition Integration: The company has recorded impairments in the past, including ₹114.065 Crore for HealthMap Diagnostics in FY2024. Future integration risks remain.

Valuation & Peer Comparison

Specific peer comparison data and valuation multiples (P/E, P/B) are not available as the price band has not been disclosed. However, the company's revenue CAGR of 29.41% positions it as a high-growth player in the Indian healthcare sector. The significant debt reduction planned via the IPO (₹5,552.76 Crore) is expected to improve future profitability through interest savings.

Bottom Line

Manipal Health Enterprises presents a compelling growth story with India's largest multispecialty hospital network and strong institutional backing. The IPO offers a clear path to deleveraging, which should boost future PAT. However, investors must weigh this against the recent decline in PAT, high debt levels, and geographic concentration risks. With the IPO opening on 29-Jul-2026, market participants will need to wait for the price band disclosure to assess valuation adequacy.

Manipal Health Enterprises, India's largest pan-India multispecialty hospital network by licensed bed capacity, will open its initial public offering (IPO) on July 29, 2026, closing on July 31, 2026. Allotment is scheduled for August 3, 2026, with listing on August 5, 2026. The company intends to deploy the majority of net proceeds—₹5,552.76 crore—toward repaying outstanding borrowings and accrued interest availed by Manipal Hospitals Private Limited, while allocating ₹574.00 crore to acquire a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (SHPL). This capital raise aims to deleverage the balance sheet and consolidate ownership in SHPL to 99.86%, addressing investor concerns over high indebtedness and minority interest leakage. Incorporated in 2010 and headquartered in Bengaluru, the company operates 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. The Board of Directors includes Dr. Hebri Sudarshan Ballal as Chairman and Dilip Jose Puthiyidathu as Managing Director.

IPO Timeline and Use of Proceeds

The IPO follows a structured timeline, with proceeds earmarked for specific strategic objectives. The two primary identified uses of proceeds total ₹6,126.76 crore, with the remainder allocated to general corporate purposes including marketing, brand building, working capital, and contingencies.

As of May 31, 2026, aggregate outstanding borrowings stood at ₹11,185.02 crore, of which 45.25% is subject to variable interest rates. The proposed NCD repayment is expected to reduce interest outflows and stabilize margins. Post-acquisition of Tranche III, the company will hold 99.86% of SHPL, enabling full operational and financial integration of this key asset.

Financial Performance

Revenue from operations grew consistently over the past three fiscal years, rising from ₹6,171.63 crore in FY2024 to ₹8,242.25 crore in FY2025, and reaching ₹10,335.75 crore in FY2026. However, profitability metrics showed volatility—profit after tax (PAT) surged to ₹1,081.67 crore in FY2025 but declined to ₹916.52 crore in FY2026 despite higher revenues, as total expenses grew by approximately 29.92% year-over-year against revenue growth of 25.40%, compressing margins. Profit before tax (PBT) also fell from ₹1,242.31 crore in FY2025 to ₹1,178.03 crore in FY2026.

Total assets nearly doubled from ₹14,072.08 crore in FY2025 to ₹24,864.50 crore in FY2026, driven primarily by a jump in non-current assets from ₹11,217.46 crore to ₹20,755.51 crore, reflecting aggressive acquisition activity. Cash used in investing activities surged to ₹7,036.74 crore in FY2026, largely funded by financing inflows of ₹4,954.44 crore. Operating cash flows remained robust at ₹2,078.40 crore in FY2026, up from ₹1,388.65 crore in FY2024, indicating strong underlying business fundamentals despite the earnings dip.

Operational Highlights

Maniphal Health Enterprises derives significant revenue from six complex specialties collectively termed CONGO-R: Cardiac Sciences, Oncology, Neurosciences, Gastro Sciences, Orthopedics, and Renal Sciences. These specialties contributed 64.30% of gross inpatient revenue in FY2026, up from 61.55% in FY2024, reflecting a consistent and growing contribution from high-acuity, high-value procedures. Insurance and third-party administrators accounted for 49.68% of gross inpatient revenue in FY2026.

Geographic concentration risk is mitigating, with Karnataka's share of revenue declining from 59.98% in FY2024 to 46.40% in FY2026, demonstrating successful diversification across 14 states and union territories. Occupancy rates remained stable at approximately 64% across FY2025 and FY2026, leaving meaningful capacity headroom for future growth.

Key Risks

The company faces several material risks that investors should evaluate carefully. High indebtedness remains the most pressing concern, with aggregate outstanding borrowings of ₹11,185.02 crore as of May 31, 2026, of which 45.25% is at variable interest rates, exposing the company to interest rate fluctuation risk. Healthcare professional retention poses structural cost pressures, with doctor professional fees constituting 22.72% of revenue, employee benefits at 14.42% of revenue, and a nurse attrition rate of 19.56% in FY2026. Operational continuity risk arises from 31 of 49 hospitals being fully or partially located on leased land. Additionally, 39 material regulatory approvals were applied for and pending as of the prospectus date, and prior goodwill impairments—₹1,140.65 million for HealthMap Diagnostics in FY2024 and ₹222.32 million for Medica TS Hospital in FY2025—raise acquisition integration concerns.